{"id":"https://openalex.org/W4238044205","doi":"https://doi.org/10.1158/1538-7445.am2019-2990","title":"Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy","display_name":"Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W4238044205","doi":"https://doi.org/10.1158/1538-7445.am2019-2990"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-2990","doi":"https://doi.org/10.1158/1538-7445.am2019-2990","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-2990","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052448809","display_name":"Shruti Bhatt","orcid":"https://orcid.org/0000-0002-2617-5082","observed_orcids":["https://orcid.org/0000-0002-2617-5082"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shruti Bhatt","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033012755","display_name":"Binyam Yilma","orcid":"https://orcid.org/0009-0007-8845-5390","observed_orcids":["https://orcid.org/0009-0007-8845-5390"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Binyam Yilma","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001646551","display_name":"Elyse A. Olesinski","orcid":"https://orcid.org/0000-0002-2717-9755","observed_orcids":["https://orcid.org/0000-0002-2717-9755"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elyse Olesinski","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086420008","display_name":"Holly Zhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly Zhu","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039924049","display_name":"Mark Alan Murakami","orcid":"https://orcid.org/0000-0001-9520-2876","observed_orcids":["https://orcid.org/0000-0001-9520-2876"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Murakami","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028053662","display_name":"Vineeth Kumar Murali","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vineeth Kumar Murali","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056530572","display_name":"Sophia Adamia","orcid":"https://orcid.org/0000-0001-5704-6040","observed_orcids":["https://orcid.org/0000-0001-5704-6040"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sophia Adamia","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026688095","display_name":"David M. Weinstock","orcid":"https://orcid.org/0000-0002-8724-3907","observed_orcids":["https://orcid.org/0000-0002-8724-3907"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Weinstock","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102705548","display_name":"Jacqueline Suen Garcia","orcid":"https://orcid.org/0000-0003-2118-6302","observed_orcids":["https://orcid.org/0000-0003-2118-6302","https://orcid.org/0000-0002-2599-7308"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline S. Garcia","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022857112","display_name":"Anthony G. Letai","orcid":"https://orcid.org/0000-0002-1993-9013","observed_orcids":["https://orcid.org/0000-0002-1993-9013"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Letai","raw_affiliation_strings":["Dana-Farber Cancer Inst., Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"2990","last_page":"2990"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.996999979019165},{"id":"https://openalex.org/keywords/mitochondrial-priming","display_name":"mitochondrial priming","score":0.746999979019165},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8519999980926514},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7620000243186951},{"id":"https://openalex.org/keywords/precision-medicine","display_name":"precision medicine","score":0.7360000014305115},{"id":"https://openalex.org/keywords/relapsed-refractory-aml","display_name":"relapsed/refractory AML","score":0.8399999737739563},{"id":"https://openalex.org/keywords/quizartinib","display_name":"quizartinib","score":0.8159999847412109},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.949999988079071},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8019999861717224},{"id":"https://openalex.org/keywords/smac-mimetics","display_name":"IAP antagonists","score":0.828000009059906},{"id":"https://openalex.org/keywords/birinapant","display_name":"birinapant","score":0.7689999938011169},{"id":"https://openalex.org/keywords/jq1","display_name":"JQ1","score":0.8180000185966492},{"id":"https://openalex.org/keywords/cdk9-inhibitor","display_name":"CDK9 inhibitor","score":0.6880000233650208},{"id":"https://openalex.org/keywords/drug-response-prediction","display_name":"drug response prediction","score":0.45899999141693115}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.7378606200218201},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6000274419784546},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5990493297576904},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.5432192087173462},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.5337214469909668},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.502291202545166},{"id":"https://openalex.org/C163763905","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision medicine","level":2,"score":0.4675387740135193},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4669996500015259},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4301450252532959},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39875873923301697},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3953418731689453},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.35279297828674316},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3488745391368866},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3210917115211487},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2512504756450653},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22961550951004028},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.11742663383483887},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-2990","doi":"https://doi.org/10.1158/1538-7445.am2019-2990","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-2990","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3146984436","https://openalex.org/W3177570246","https://openalex.org/W4415217298","https://openalex.org/W2496574993","https://openalex.org/W4389234644","https://openalex.org/W2992226428","https://openalex.org/W2621779581","https://openalex.org/W2016398606","https://openalex.org/W3212422879","https://openalex.org/W4392447594"],"abstract_inverted_index":{"Abstract":[0],"The":[1,25,240],"major":[2,157],"focus":[3],"of":[4,28,38,46,137,148,197,204,211,237,268,277,315,339,349,353,405,468],"drug":[5,78,265],"development":[6],"in":[7,172,208,253,298,317,320,335,400],"AML":[8,105,228,407],"has":[9],"shifted":[10],"to":[11,18,35,50,62,91,131,140,206,263,279,293,327,330,351,361,380,394,424,459],"targeted":[12,30,53,133],"agents":[13,332,363],"because,":[14],"despite":[15],"initial":[16],"sensitivity":[17,89,350],"conventional":[19],"chemotherapy,":[20],"durable":[21],"remissions":[22],"are":[23,304],"limited.":[24],"clinical":[26],"implementation":[27],"effective":[29],"therapies":[31,54,319],"still":[32],"lags":[33],"due":[34],"the":[36,43,202,274,313,321,354,384,401,469],"lack":[37],"predictive":[39,275],"biomarkers.":[40],"To":[41,98,311],"make":[42],"best":[44],"use":[45],"existing":[47],"therapy":[48,399,426,464],"and":[49,134,181,189,222,347],"identify":[51],"new":[52],"we":[55,108,200,287,324,376],"adopted":[56],"a":[57,100,182,195,371,420,428],"broadly":[58],"applicable":[59],"functional":[60,457],"approach":[61,379,458],"precision":[63,281,421],"medicine":[64,282,422],"called":[65],"\u201cdynamic":[66],"BH3":[67,93,187],"profiling\u201d":[68],"(DBP).":[69],"DBP":[70,151,205,249,258,278,290,316,391],"measures":[71],"early":[72],"death":[73,82],"signaling":[74,83],"induced":[75,170,325],"by":[76,86,390],"short-term":[77],"exposure.":[79],"Increased":[80],"cell":[81],"is":[84],"reflected":[85],"increased":[87,244],"mitochondrial":[88,142,345,386],"(priming)":[90],"standardized":[92],"peptides":[94],"mimicking":[95],"pro-apoptotic":[96],"proteins.":[97],"develop":[99],"personalized":[101],"therapeutic":[102],"strategy":[103],"for":[104,365,427,472],"using":[106],"DBP,":[107],"utilized":[109],"17":[110],"patient-derived":[111],"xenografts":[112],"(PDX)":[113],"established":[114],"from":[115,126,165],"de":[116],"novo,":[117],"primary":[118],"refractory":[119],"or":[120],"relapsed":[121,322],"(R/R)":[122],"patients.":[123,408],"Human":[124],"myeloblasts":[125],"xenotransplanted":[127],"mice":[128],"were":[129],"exposed":[130],"30":[132],"3":[135],"standard":[136],"care":[138],"drugs":[139,169],"determine":[141],"responses":[143,152,210],"via":[144,248,333],"DBP.":[145],"Unsupervised":[146],"clustering":[147],"ex":[149,245],"vivo":[150,209,246,254,336],"segregated":[153],"PDXs":[154,162,261,299],"into":[155],"two":[156],"clusters,":[158],"where":[159],"treatment":[160],"na\u00efve":[161],"clustered":[163],"distinctly":[164],"R/R":[166,406],"PDXs.":[167,198],"Most":[168],"priming":[171,238,247,346,388],"only":[173],"selective":[174],"PDXs,":[175],"including":[176],"kinase":[177],"inhibitors,":[178],"epigenetic":[179],"modifiers,":[180],"SMAC":[183],"mimetic.":[184],"In":[185,409],"contrast,":[186],"mimetics":[188],"CDK9":[190],"inhibitors":[191],"showed":[192,243,251,342],"activity":[193,297],"across":[194,226],"majority":[196],"Next,":[199],"validated":[201],"ability":[203],"predict":[207,295],"single-agent":[212],"birinapant":[213],"(SMAC":[214],"mimetic),":[215],"JQ-1":[216],"(BRD-4":[217],"inhibitor),":[218,221],"quizartinib":[219,296],"(FLT-3":[220],"venetoclax":[223],"(BCL-2":[224],"inhibitor)":[225],"6":[227],"PDX":[229,328],"models,":[230],"prioritized":[231],"based":[232,308],"on":[233,309],"their":[234,264],"greatest":[235,252],"range":[236],"responses.":[239],"models":[241,329],"that":[242,257,289,358,383,414],"also":[250],"responses,":[255],"indicating":[256],"can":[259],"rank":[260],"according":[262],"sensitivities":[266],"(AUC":[267],"ROC":[269],"0.87,":[270],"p<0.005).":[271],"By":[272],"comparing":[273],"power":[276],"other":[280],"tools":[283],"such":[284],"as":[285,306,419],"genomics,":[286],"found":[288],"was":[291],"able":[292],"accurately":[294],"with":[300],"WT":[301],"FLT-3,":[302],"which":[303,368],"categorized":[305],"unresponsive":[307],"genomics.":[310],"test":[312],"applicability":[314],"assigning":[318],"setting,":[323],"resistance":[326,360],"single":[331,362],"long-term":[334],"selection.":[337],"Myeloblasts":[338],"relapsing":[340],"clone":[341],"reduced":[343],"baseline":[344],"loss":[348],"most":[352],"agents.":[355],"This":[356],"suggested":[357],"acquired":[359],"selects":[364],"apoptosis-refractory":[366],"clones":[367],"then":[369],"drive":[370],"pan-drug":[372],"resistant":[373],"phenotype.":[374],"Finally,":[375],"applied":[377],"this":[378],"humans,":[381],"showing":[382],"pretreatment":[385],"apoptotic":[387],"determined":[389],"identifies":[392],"responders":[393],"lenalidomide":[395],"plus":[396],"MEC":[397],"combination":[398],"phase":[402],"1":[403],"trial":[404],"summary,":[410],"our":[411],"results":[412],"suggest":[413],"mitochondria-based":[415],"measurements":[416],"may":[417],"serve":[418],"tool":[423],"guide":[425],"heterogeneous":[429],"population.":[430],"Citation":[431],"Format:":[432],"Shruti":[433],"Bhatt,":[434],"Binyam":[435],"Yilma,":[436],"Elyse":[437],"Olesinski,":[438],"Holly":[439],"Zhu,":[440],"Mark":[441],"Murakami,":[442],"Vineeth":[443],"Kumar":[444],"Murali,":[445],"Sophia":[446],"Adamia,":[447],"David":[448],"M.":[449],"Weinstock,":[450],"Jacqueline":[451],"S.":[452],"Garcia,":[453],"Anthony":[454],"Letai.":[455],"Individualized":[456],"tailoring":[460],"acute":[461],"myeloid":[462],"leukemia":[463],"[abstract].":[465],"In:":[466],"Proceedings":[467],"American":[470],"Association":[471],"Cancer":[473,487],"Research":[474],"Annual":[475],"Meeting":[476],"2019;":[477],"2019":[478],"Mar":[479],"29-Apr":[480],"3;":[481],"Atlanta,":[482],"GA.":[483],"Philadelphia":[484],"(PA):":[485],"AACR;":[486],"Res":[488],"2019;79(13":[489],"Suppl):Abstract":[490],"nr":[491],"2990.":[492]},"counts_by_year":[],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2022-05-12T00:00:00"}